How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,845 results for

Tongue Carcinoma

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1701. The first 15 cm are important in upper gastrointestinal endoscopy. (PubMed)

The first 15 cm are important in upper gastrointestinal endoscopy. 8343634 1993 09 07 2008 11 20 0959-8138 306 6894 1993 Jun 26 BMJ (Clinical research ed.) BMJ The first 15 cm are important in upper gastrointestinal endoscopy. 1742 Rai A S AS Southampton General Hospital. Steer H H eng Case Reports Journal Article England BMJ 8900488 0959-8138 AIM IM Carcinoma, Squamous Cell complications Endoscopy, Gastrointestinal methods Gastrointestinal Hemorrhage etiology Humans Male Middle Aged Tongue

Full Text available with Trip Pro

1993 BMJ : British Medical Journal

1702. Malignancy of the larynx: (Experimentation on Animal, Construction of Biologic Neo-Larynx and Rehabilitation of the Laryngectomee—20 Years Experience) (PubMed)

Malignancy of the larynx: (Experimentation on Animal, Construction of Biologic Neo-Larynx and Rehabilitation of the Laryngectomee—20 Years Experience) Squamous cell carcinoma is by far the commonest malignancy of the larynx and I would confine my present paper mainly to this along with the management and post-operative rehabilitation after total laryngectomy. High survival rate in majority of the cases, if diagnosed and treated early and adequately, provokes and encourages the interested (...) knowledge) and a Neo-Glottis are ingeniously constructed in order to enable the laryngectomee to phonate tracheooesophageally (c.f. pharyngoesophageally). The Neo-Glottis is transversely disposed since it offers better protection against aspiration than the vertically disposed one. The Neo-Epiglottis is constructed from the posterior tracheal wall, inferiorly based, or from the superiorly based tongue-shaped flap, raised from the full-thickness membranous posterior tracheal wall, or from the anterior

Full Text available with Trip Pro

1997 Indian Journal of Otolaryngology and Head & Neck Surgery

1703. [Intra-arterial preoperative chemotherapy versus preoperative radiotherapy]. (PubMed)

. Germany Strahlenther Onkol 8603469 0179-7158 0 Antibiotics, Antineoplastic 0 Antineoplastic Agents 3Z8479ZZ5X Epirubicin Q20Q21Q62J Cisplatin IM Antibiotics, Antineoplastic administration & dosage Antineoplastic Agents administration & dosage Carcinoma, Squamous Cell drug therapy radiotherapy surgery Carotid Artery, External Chemotherapy, Adjuvant Cisplatin administration & dosage Combined Modality Therapy Epirubicin administration & dosage Follow-Up Studies Humans Infusions, Intra-Arterial Mouth (...) Floor Mouth Neoplasms drug therapy radiotherapy surgery Neoplasm Recurrence, Local prevention & control Odds Ratio Osteoradionecrosis etiology Preoperative Care Quality of Life Radiotherapy adverse effects Radiotherapy Dosage Radiotherapy, Adjuvant Surveys and Questionnaires Time Factors Tongue Neoplasms drug therapy radiotherapy surgery 2001 3 10 10 0 2001 4 3 10 1 2001 3 10 10 0 ppublish 11233834

2001 Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] Controlled trial quality: uncertain

1704. Clinical significance of radiation therapy combined with chemotherapy. (PubMed)

Clinical significance of radiation therapy combined with chemotherapy. With the aim of reducing the side-effects in the surrounding healthy tissues, and/or improving the local control rate, radiotherapy combined with chemotherapy has been used to treat carcinoma of the esophagus, of the tongue, and of the paranasal sinuses. In the treatment of esophageal cancer, a dose of bleomycin too small to demonstrate clinical activity on its own is shown to potentiate the action of radiation (...) with an enhancement ratio lying between 1.3 and 1.7 (Table 1). From the concept of 'therapeutic ratio' a 'two-phase' treatment modality (Table 2) was proposed, because many anticancer drugs or radiosensitizers available today influence not only the tumor tissue but also the surrounding healthy tissues. 'Two-phase' treatment was applied to cancer of the tongue (Table 3) and to cancer of the paranasal sinuses (Table 4). The appearance of the chronical complications such as the osteoradionecrosis of the mandible

1980 Strahlentherapie Controlled trial quality: uncertain

1705. Induction chemotherapy in primary resectable head and neck tumors - a prospective randomized trial. (PubMed)

of the hypopharynx and base of tongue is too small for a statistically significant statement, but preliminary data indicate a better overall and disease-free survival without chemotherapy in these patients. Therefore, we recommend controlled trials with induction chemotherapy in patients with primary resectable carcinomas of the oral cavity and the tonsil, stages T2-T3 and N0-N2, prior to surgery but not in patients with cancer of the hypopharynx and base of the tongue. (...) of carboplatin/5-FU prior to surgery and radiotherapy (arm A, 49 patients) or standard treatment with surgery and radiotherapy (arm B, 47 patients). Patients were stratified by primary tumor site and neck disease. After a follow-up of 12-48 months overall survival was 72% in arm A and 53% in arm B (n.s.). Considering only the patients with cancer of the oral cavity and the tonsil overall survival was 88% in arm A and 44% in arm B (p<0.05). As of today, the number of patients with carcinomas

1994 International journal of oncology Controlled trial quality: uncertain

1706. Thyroid papillary carcinoma arising in ectopic thyroid tissue within a neck branchial cyst (PubMed)

Thyroid papillary carcinoma arising in ectopic thyroid tissue within a neck branchial cyst Thyroid gland derives from one median anlage at the base of the tongue, and from the two fourth branchial pouches. A number of anomalies may occur during their migration. These can be in form of ectopic tissues, which are frequently found along the course of thyroglossal duct and rarely in other sites, many of these may develop same diseases as the thyroid gland.A 36-years-old female presented with a 3 (...) month history of left side neck mass. The mass disappeared following aspiration of brown colored fluid, which on cytological examination showed cells with nuclear irregularities that warranted the resection of the lesion. The histology demonstrated a thyroid papillary carcinoma arising within the branchial cyst. Thereafter, the patient underwent a total thyroidectomy with central lymph nodes dissection. Histology showed a multifocal papillary carcinoma with central lymph nodes metastases. Only four

Full Text available with Trip Pro

2006 World journal of surgical oncology

1707. Topoisomerase II trapping agent teniposide induces apoptosis and G2/M or S phase arrest of oral squamous cell carcinoma (PubMed)

for application to the patients with oral cancer.Human tongue squamous cell carcinoma cell line, Tca8113, was used. Cells were incubated with different concentrations of VM-26 for a variety of time span. Cisplatin (CDDP) was employed as a control reagent. MTT assay was used to assess the inhibitory rate of Tca8113 growth. Flow cytometer (FCM), transmission electronic microscope (TEM) and fluorescence staining were employed for determining the cell apoptotic rate. Cell cycle distribution of Tca8113 incubated (...) Topoisomerase II trapping agent teniposide induces apoptosis and G2/M or S phase arrest of oral squamous cell carcinoma Teniposide (VM-26) has been widely used in the treatment of small cell lung cancer, malignant lymphoma, breast cancer, etc. However, there are few reports on VM-26 against oral cancers. The present study was designed to identify the effect of VM-26 against oral squamous cell carcinoma in vitro, and to provide evidence for the feasibility and effectiveness of VM-26

Full Text available with Trip Pro

2006 World journal of surgical oncology

1708. Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line (PubMed)

a cisplatin-sensitive cell line, Tca8113, which was derived from moderately-differentiated tongue squamous cell carcinoma. Global gene expression in this resistant cell line and its sensitive parent cell line was analyzed using Affymetrix HG-U95Av2 microarrays. Candidate genes involved in DNA repair, the MAP pathway and cell cycle regulation were chosen to validate the microarray analysis results. Cell cycle distribution and apoptosis following cisplatin exposure were also investigated.Cisplatin (...) Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line Cisplatin is widely used for chemotherapy of head and neck squamous cell carcinoma. However, details of the molecular mechanism responsible for cisplatin resistance are still unclear. The aim of this study was to identify the expression of genes related to cisplatin resistance in oral squamous cell carcinoma cells.A cisplatin-resistant cell line, Tca/cisplatin, was established from

Full Text available with Trip Pro

2006 BMC cancer

1709. Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients

Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00201383 Recruitment Status : Completed First Posted : September 20, 2005

2005 Clinical Trials

1710. Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma

Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Chemoprevention Study of Oral Cavity (...) Squamous Cell Carcinoma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00201279 Recruitment Status : Completed First Posted : September 20, 2005 Last Update Posted : September 20, 2005 Sponsor: National Health Research Institutes, Taiwan Collaborators: National Taiwan University Hospital Changhua

2005 Clinical Trials

1711. Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma

) of the base of the tongue, posterior lateral pharyngeal wall, hypopharynx or larynx. Condition or disease Intervention/treatment Phase Head Neck Cancer Combination Product: Medpulser Electroporation with Bleomycin Procedure: Surgical Excision Phase 3 Detailed Description: Recurrent tumors in head and neck squamous cell carcinoma usually have a poor prognosis. In patients suitable for salvage surgery of their recurrent disease, the success rate for local control has been reported to be 40-50%. The surgical (...) of Function Status After Either Medpulser Electroporation With Intratumoral Bleomycin Therapy or Surgery in Patients With Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Base of the Tongue, Posterior Lateral Pharyngeal Wall, Hypopharynx, or Larynx That Have Failed Primary Curative Therapy Actual Study Start Date : November 2004 Actual Primary Completion Date : June 2007 Actual Study Completion Date : June 2007 Resource links provided by the National Library of Medicine related topics

2005 Clinical Trials

1712. Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.

: Written informed consent. Aged between 18 and 80, inclusive. Karnofsky functional status >= 70% at the time of enrolment in study. Life expectancy of more than 3 months. Histologically confirmed diagnosis of oropharyngeal squamous cell carcinoma: base of tongue, vallecula, tonsil and tonsillar fossa and pillars, glossotonsillar sulcus, inferior surface of the soft palate, uvula and lateral and posterior oropharyngeal wall. Stage III or IV with no evidence of distant metastasis (IVA or IV B) Patients (...) Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma. Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2005 Clinical Trials

1713. Elective vs Therapeutic Neck Dissection in Treatment of Early Node Negative Squamous Carcinoma of Oral Cavity

, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Histologically proven T1 or T2 N0 M0 (clinical) squamous cell carcinoma of the buccal mucosa, lower alveolus, oral tongue and floor of mouth. Surgery is the preferred treatment and the primary tumor can be excised with clear margins via the per-oral route. No history of a prior malignancy in the head and neck region. No prior malignancy outside the head and neck region in the preceding 5 years (...) Elective vs Therapeutic Neck Dissection in Treatment of Early Node Negative Squamous Carcinoma of Oral Cavity Elective vs Therapeutic Neck Dissection in Treatment of Early Node Negative Squamous Carcinoma of Oral Cavity - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2005 Clinical Trials

1714. Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)

Eligible for Study: 18 Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Histologically confirmed, primary only with laryngectomy respectable squamous-cell carcinoma of the larynx or hypopharynx T3-T4a carcinoma of the glottis T2-T4a carcinoma of the supraglottic, only controllable by laryngectomy and if applicable by root of tongue segmental resection T2-T4a carcinoma of the hypopharynx only controllable by laryngectomy (...) Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA) Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2007 Clinical Trials

1715. Patient Selection for Hypoxia Modifying Treatments in Larynx Carcinomas

-classification (UICC 1997, appendix I): T3-4 glottic or supraglottic carcinoma T2 glottic carcinoma with impaired cord mobility or subglottic extension T2 supraglottic carcinoma with invasion of mucosa of base of tongue or vallecula or invasion of the medial wall of the piriform sinus. any N-stage, M0. WHO performance status 0 or 1. Age > 18 years. Written informed consent. Treatment in the ARCON phase III trial Exclusion Criteria: Prior or concurrent treatment for this tumour. Severe stridor and adequate (...) Patient Selection for Hypoxia Modifying Treatments in Larynx Carcinomas Patient Selection for Hypoxia Modifying Treatments in Larynx Carcinomas - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Patient

2005 Clinical Trials

1716. Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck

Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00096174 Recruitment Status : Completed First Posted

2004 Clinical Trials

1717. Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

IVB Squamous Cell Carcinoma of the Oropharynx Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVB Verrucous Carcinoma of the Oral Cavity Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IVC Squamous Cell Carcinoma of the Oropharynx Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVC Verrucous Carcinoma of the Oral Cavity Tongue Cancer Drug: bortezomib Drug: irinotecan hydrochloride Other: laboratory biomarker (...) Squamous Cell Carcinoma of Head and Neck Nasopharyngeal Carcinoma Paranasal Sinus Neoplasms Tongue Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Respiratory Tract Diseases Otorhinolaryngologic Diseases Otorhinolaryngologic Neoplasms Head and Neck Neoplasms Neoplasms by Site Respiratory Tract Neoplasms Pharyngeal Neoplasms Pharyngeal Diseases Stomatognathic Diseases Nasopharyngeal Neoplasms Nasopharyngeal Diseases Nose Neoplasms Nose

2005 Clinical Trials

1718. Discontinuous vs. in-continuity neck dissection in carcinoma of the oral cavity. Experience of two oncologic hospitals. (PubMed)

Discontinuous vs. in-continuity neck dissection in carcinoma of the oral cavity. Experience of two oncologic hospitals. Many Authors have discussed the best indication and extension of neck dissection, but few have studied the surgical approach considering the continuity of neck dissection with the primary tumour. This retrospective study refers to patients submitted to major surgery between 1996 and 2001 for floor of mouth and oral tongue squamous cell carcinoma, at the Head and Neck Surgery

Full Text available with Trip Pro

2007 Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale

1719. Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx

or disease Intervention/treatment Phase Lip and Oral Cavity Cancer Oropharyngeal Cancer Stage 0 Lip and Oral Cavity Cancer Stage 0 Oropharyngeal Cancer Tongue Cancer Biological: Ad5CMV-p53 gene Other: laboratory biomarker analysis Phase 1 Phase 2 Detailed Description: OBJECTIVES: I. Determine the acute toxic effects of Ad5CMV-p53 gene administered as an oral rinse and as an intramucosal injection in patients with diffuse premalignant carcinoma of the oral cavity or oral pharynx. II. Determine the maximum (...) Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2003 Clinical Trials

1720. A cell proteomic approach for the detection of secretable biomarkers of invasiveness in oral squamous cell carcinoma. (PubMed)

A cell proteomic approach for the detection of secretable biomarkers of invasiveness in oral squamous cell carcinoma. To identify potential biomarkers of invasiveness in oral squamous cell carcinoma.A pilot proteomic study for the identification of secreted and cleaved proteins that can serve as potential biomarkers for head and neck carcinoma invasiveness.Two primary cell lines and their variants were established from 2 oral squamous cell carcinoma human tissue samples with distinct invasive (...) phenotypes. The cell lines were confirmed to maintain the invasive capacity of the original cancer when implanted into the tongues of immunocompromised RAG-2/gamma(c) mice.Invasiveness was assessed by the capacity of cells to invade through a matrigel matrix using the Boyden chamber assay and correlated with the invasiveness seen clinically and histologically in patients. In parallel, cell lines were grown in serum-free conditioned medium, which was then used to identify secreted and/or cleaved proteins

Full Text available with Trip Pro

2007 Archives of Otolaryngology Head and Neck Surgery

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>